Germany-based multinational corporation Bayer AG (ETR: BAYN) is determined to continue investing in China, as stated by Matthias Berninger, Executive Vice-President of Public Affairs, Science, Sustainability, and HSE at Bayer. Berninger’s comments came in an interview with China Daily in anticipation of the China International Import Expo, scheduled for November 5-10.
Key Drivers for Investment in China
Berninger highlighted several positive aspects of the Chinese market that will drive further investment from Bayer. These include a significant number of innovations occurring within the country, the capability to develop drugs nearly simultaneously across the US, Europe, and China, and an increasing ability to secure reimbursement coverage on the National Reimbursement Drug List (NRDL).
The Importance of Global Collaboration
Berninger also addressed the negative impact of recent efforts to decouple China from the United States, emphasizing the critical need for global collaboration in healthcare. He stated, “If you think about a disease like cancer, for example, the war against cancer requires that we collaborate across the borders, and that our regulatory systems are harmonized as much as possible.” This underscores the importance of finding the right balance between controlling costs in the health system and fostering innovation, a message that governments worldwide must understand and embrace.
Conclusion
Bayer AG’s commitment to further investment in China reflects the company’s confidence in the potential for innovation and growth within the Chinese market. Despite global challenges, Bayer AG remains focused on the opportunities that global collaboration presents, particularly in the critical healthcare sector.-Fineline Info & Tech
